

Amendments to the Claims:

1 – 44. (Canceled)

45. (Currently amended) A method for suppressing the growth of blood vessel tissues caused by expression of tissue factor in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an antibody having Factor X binding inhibitory ~~neutralizing~~ activity to human tissue factor (human TF).

46. (Previously presented) The method according to claim 45 wherein said antibody is a polyclonal antibody.

47. (Previously presented) The method according to claim 45 wherein said antibody is a monoclonal antibody.

48. (Previously presented) The method according to claim 45 wherein said antibody is a recombinant antibody.

49. (Previously presented) The method according to claim 45 wherein said antibody is an altered antibody.

50. (Previously presented) The method according to claim 49 wherein said altered antibody is a chimeric antibody or a humanized antibody.

51. (Currently amended) The method according to claim 50 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2, wherein said humanized antibody is chosen from the group consisting of the antibody heavy and light chain pairings ~~parings~~ of SEQ ID NO: 29 and SEQ ID NO: 88; SEQ ID NO: 59 and SEQ ID NO: 88; and SEQ ID NO: 59 and SEQ ID NO: 98, wherein the constant region is a constant region of human IgG.

52. (Previously presented) The method according to claim 45 wherein said antibody is a modified antibody.

53. (Previously presented) The method according to claim 52 wherein said modified antibody is an antibody fragment Fab, F(ab')₂, or Fv, or a single chain Fv (scFv).

54. (Previously presented) The method according to claim 50, wherein said altered antibody comprises H chains and L chains wherein the H chain contains CDRs contained in SEQ ID NO: 59 and the L chain contains CDRs contained in SEQ ID NO: 98.

55. (New) The method according to claim 45, wherein the antibody having Factor X binding inhibitory activity to human TF is an antibody which binds to the same site as a site of the human TF to which version i-b2 antibody binds, wherein the version i-b2 antibody is an antibody in which variable regions have SEQ ID NO: 59 and SEQ ID NO: 98, and constant regions are of human IgG.

56. (New) The method according to claim 45, wherein the antibody having Factor X binding inhibitory activity to human TF has CDRs which are the same as CDRs of version i-b2 antibody, wherein the version i-b2 antibody is an antibody in which variable regions have SEQ ID NO: 59 and SEQ ID NO: 98, and constant regions are of human IgG.